| Name | Title | Contact Details |
|---|
ALFA International is the premier global network for independent law firms. Founded in 1980, it was the first and continues to be one of the largest and strongest legal networks. We have 140 member firms throughout the world. Our 80 US firms maintain offices in 95 of the 100 largest metropolitan areas. Our 60 international firms are located throughout Europe, Asia, Australia/New Zealand, Africa, Canada, Mexico and South America. ALFA Internationals mission is to provide high quality, cost-efficient legal services wherever our clients need them. The ALFA International model enables our members to use their local expertise to deliver highly effective legal solutions, often drawing upon the collective wisdom and experience of other member firms. ALFA International clients have the benefit of a geographically comprehensive network of exceptional law firms and accomplished trial and business counsel. Our member firms meet high standards to be part of the ALFA International network and are well respected by their peers. Our members establish broad, deep relationships with each other by attending ALFA International CLE seminars throughout the year and working together on compendia, seminar programming, and most importantly, client matters. As a result, referrals among ALFA International firms represent partnerships between trusted friends and colleagues. Our many events also provide corporate counsel with the opportunity to network among ALFA International lawyers and their peer in-house lawyers. In addition to the Practice Groups below, our member firms also have expertise in Admiralty & Maritime, Alternative Dispute Resolution, Antitrust & Trade Regulation, Bankruptcy, Corporate & Securities, Environmental Law, Estate Planning & Wealth Transfer, Foreign Investment, Government Relations, Lobbying, & Administrative Law, Immigration, M&A, Oil & Gas, Tax & Venture Capital & Financing. To learn more, please visit us at www.alfainternational.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Familie specializes in talent representation across sports and music.